fluorodeoxyglucose f18 has been researched along with Gaucher Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bressman, S; Brüggemann, N; Condefer, K; Dhawan, V; Hagenah, J; Klein, C; Kornreich, R; Ozelius, L; Palmese, C; Pastores, G; Roe, A; Sathe, S; Saunders-Pullman, R; Stanley, K; Tagliati, M | 1 |
| Ishii, K; Itokawa, K; Kawai, N; Shimazu, K; Tamura, N | 1 |
2 other study(ies) available for fluorodeoxyglucose f18 and Gaucher Disease
| Article | Year |
|---|---|
Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Gaucher Disease; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Neuropsychological Tests; Olfaction Disorders; Parkinson Disease; Phenotype; Positron-Emission Tomography; Ultrasonography, Doppler, Transcranial | 2010 |
Parkinsonism in type I Gaucher's disease.
Topics: 3-Iodobenzylguanidine; Adult; Age of Onset; Brain; Fluorodeoxyglucose F18; Gaucher Disease; Heart; Humans; Male; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2006 |